Progesterone Antibody (XM207) - BSA Free

• Reactivity: Hu
• Applications: ELISA
• Clone: XM207
• Clonality: Monoclonal
• Host: Mouse
• Conjugate: Unconjugated
• Format: BSA Free

Progesterone Antibody (XM207) - BSA Free Summary

• Immunogen: Hybridoma clone has been derived from hybridization of Sp2/0 myeloma cells with spleen cells of Balb/c mice immunized with purified progesterone conjugated with BSA.
• Localization: Secreted
• Specificity: Progesterone, Ka = 3.0 x 10^9_ M^-1. Not cross-reacting with BSA. Cross-reactivity (%): Progesterone (100); 17-Hydroxyprogesterone (1.0); 11-Hydroxyprogesterone (25); 5-alpha-pregnane-3,20 dionene (10.5); Corticosterone (0.01); Pregnenolone (0.9); Deoxycorticosterone (0.30); Deoxycortisol (0.03); Cortisol (0.002)
• Isotype: IgG2b
• Clonality: Monoclonal
• Host: Mouse
• Purity: Ion exchange chromatography

Applications/Dilutions

• Dilutions:
  • ELISA 1:100-1:2000

Packaging, Storage & Formulations

• Storage: Store at 4C. Do not freeze.
• Buffer: 10mM Tris (pH 7.5) and 0.15M NaCl
• Preservative: 0.05% Sodium Azide
• Purity: Ion exchange chromatography

Alternate Names for Progesterone Antibody (XM207) - BSA Free

• 4-Pregnen-3,20-dione
• Progesterone

Background

Progesterone plays a central role in the reproductive events associated with the establishment and maintenance of pregnancy. Progesterone receptor, a member of the steroid receptor superfamily, mediates the physiologic effects of progesterone. The PGR gene uses separate promoters and translational start sites to produce 2 isoforms, PRA and PRB, which are identical except for an additional 165 amino acids present only in the N terminus of PRB. Although PRA and PRB share several structural domains, they are distinct transcription factors that mediate their own response genes and physiologic effects with little overlap. It is composed of three domains: a modulating N terminal domain, a DNA binding domain and a C terminal steroid binding domain. Progesterone levels 1. men 30-60 pg/0.1ml 2. women pre ovulatory phase: 20-160 pg/0.1ml; ovulatory phase: 1,000-1,700 pg/0.1ml; post ovulatory phase: 1,000-1,700 pg/0.1ml; Pregnant: 16-18 weeks: 300-800 pg/0.1ml; 28-30 weeks: 6,500-14,700 pg/0.1ml; 38-40 weeks: 12,000-19,000 pg/0.1ml.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.